Compare STBA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | HROW |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1995 | 2008 |
| Metric | STBA | HROW |
|---|---|---|
| Price | $48.55 | $29.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $53.33 | ★ $65.00 |
| AVG Volume (30 Days) | 260.6K | ★ 601.4K |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | 2.35 | ★ 71.43 |
| EPS | ★ 1.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.87 | $28.59 |
| Revenue Next Year | $3.75 | $53.17 |
| P/E Ratio | $24.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.38 | $27.00 |
| 52 Week High | $53.50 | $54.98 |
| Indicator | STBA | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 24.37 |
| Support Level | $47.65 | $28.54 |
| Resistance Level | $48.70 | $35.43 |
| Average True Range (ATR) | 0.85 | 1.27 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 40.52 | 29.20 |
S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.